Ahead of its listing, shares of Valiant Organics were commanding a premium Rs 20 per equity share in the grey market, suggesting a listing pop of around 15 per cent over the issue.
Valiant Laboratories’ FY23 operating margins stand at 10 percent, which is almost half, compared to other peers like Granules and Alkyl Amines Chemicals.
Valiant Laboratories IPO |that focuses on manufacturing Paracetamol intends to raise Rs 152.46 crore via public issue at the upper price band, which comprises only a fresh issue component.
Valiant Organics Ltd settled with capital markets regulator Sebi a case concerning flouting of alleged disclosure rules by paying Rs 10 lakh as the settlement amount.
This came after the company filed a settlement application with Sebi proposing to settle the enforcement proceedings that may